Hims Stock In Focus As Benefits Program Expands Before Earnings

• Hims & Hers Health recently expanded its Hims & Hers Benefits program, adding Grüns, Medjet, Tonal, and Viome to offer subscribers nutritional support, home strength training, microbiome insights, and emergency medical transport without retaining profit on these partner perks.
• This move signals a push to deepen subscriber value beyond core telehealth visits and may influence how durable and broad Hims & Hers Health’s customer relationships become across multiple wellness categories.
• We will now look at how this broader Hims & Hers Health benefits bundle might influence the investment narrative already built around AI driven telehealth.

Scan beyond Hims & Hers Health and see which other digital health players are building sticky subscription ecosystems with 35 healthcare AI stocks

Hims & Hers Health Investment Narrative Recap

To own Hims & Hers Health, you need to believe the telehealth model can turn nearly 3 million recurring subscribers, higher complexity treatments and international reach into durable relationships that eventually support stronger profitability. In the short term, the focus is on execution in GLP 1 weight loss, testosterone and AI automation, plus the upcoming November 9 earnings update.

The biggest near term risk still appears operational. Management is funding heavy AI, pharmacy and lab investments while the business remains loss making on a GAAP basis and free cash flow was recently negative US$68 million. The new benefits bundle helps engagement but does not materially change those margin and cash questions yet.

The most relevant recent development for that equation is the temporary HHS approval for peptide compounding. This opens a potential new product stream that leans on the firm’s expanding lab footprint and at home diagnostics, and it connects directly to existing hormone and weight focused specialties Hims & Hers Health is already building out.

For investors, the key question is whether peptides become another sticky subscription category or remain niche. Strong uptake could support the view that heavy infrastructure spending and more than 1 million square feet of pharmacy and lab capacity are increasingly utilized. Weak traction would leave the cost base elevated while regulatory and payment scrutiny, including dispute monitoring from Visa, remain an ongoing overhang.

Hims & Hers Health's current analyst story points to revenues of US$4.6b and earnings of US$235.7 million by 2029, built on assumptions of 21.7% yearly revenue growth and a shift from today’s earnings loss of US$142.0 million to that future profit. This would mean an earnings swing of roughly US$377.7 million over the period.

Uncover why Hims & Hers Health's fair value indicates a 20% potential upside to its current price, which could narrow quickly.

Exploring Other Perspectives

Some of the most optimistic analysts highlight a different catalyst for Hims & Hers Health. They treat AI driven vertical integration as the main upside, with prior forecasts reaching US$5.9b in 2029 revenue and US$390.9 million in earnings. Those estimates were set before this expanded benefits bundle, so you may see those narratives shift as expectations reset.

Explore 16 other Hims & Hers Health fair value estimates, including one that suggests up to 558% upside from the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider your own analysis and judgment.

• A great starting point for your Hims & Hers Health research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• See our latest analysis for Hims & Hers Health. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, which makes it easier to evaluate Hims & Hers Health's overall financial position at a glance.

Looking for more investment ideas beyond Hims & Hers Health?

If the Hims & Hers Health story has sharpened your thinking on digital health and subscriptions, you can use that same lens to scan a broader watchlist. The Simply Wall St Screener lets you filter for specific financial traits so you can quickly narrow the field to businesses that fit your own risk tolerance and return goals.

• If resilience matters most to you, you can start with a set of 30 resilient stocks with low risk scores that score well on stability and balance sheet strength.
• For investors focusing on mispriced quality, you can look at a 41 high quality undervalued stocks based on fundamentals rather than hype.
• If you prefer to back smaller companies before they become widely followed, you might consider a 19 high quality undiscovered gems that already show solid underlying metrics.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com